Study guide

20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy

Key Takeaways Explain This Topic AI

KDIGO criteria stage AKI using serum creatinine increases ( ≥ 0.3 mg/dL \ge 0.3\text{ mg/dL} ≥ 0.3 mg/dL in 48h or ≥ 1.5 × \ge 1.5\times ≥ 1.5 × baseline) and oliguria duration ( < 0.5 mL/kg/h <0.5\text{ mL/kg/h} < 0.5 mL/kg/h for ≥ 6 hours \ge 6\text{ hours} ≥ 6 hours ).

Pre-renal azotemia features an intact tubular response ( FE Na < 1 % \text{FE}_{\text{Na}} < 1\% FE Na ​ < 1% , urine osmolality > 500 mOsm/kg >500\text{ mOsm/kg} > 500 mOsm/kg , BUN : Cr > 20 : 1 \text{BUN}:\text{Cr} > 20:1 BUN : Cr > 20 : 1 ), contrasting with acute tubular necrosis ( FE Na > 2 % \text{FE}_{\text{Na}} > 2\% FE Na ​ > 2% , urine osmolality < 350 mOsm/kg <350\text{ mOsm/kg} < 350 mOsm/kg , muddy brown granular casts).

Absolute emergent indications for renal replacement therapy are summarized by the AEIOU mnemonic: refractory Acidosis, severe hyperkalemic Electrolyte crisis, dialyzable Intoxications, refractory fluid Overload, and severe symptomatic Uremia.

Regional citrate anticoagulation (RCA) is the gold standard for CRRT circuits, chelating ionized calcium to < 0.35 mmol/L <0.35\text{ mmol/L} < 0.35 mmol/L pre-filter while avoiding systemic anticoagulation, monitored by the total-to-ionized calcium ratio ( > 2.5 >2.5 > 2.5 warns of citrate toxicity).

Last updated: October 2026

20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy

Acute Kidney Injury (AKI) occurs in up to 50 % 50\% 50% of critically ill patients and is an independent predictor of intensive care mortality. Mastery of the staging systems, physiological differentiation between pre-renal and intrinsic injury, emergent indications for renal replacement therapy (RRT), and physical principles of Continuous Renal Replacement Therapy (CRRT) is essential for EDAIC Part I candidates.

The KDIGO Classification of AKI (2012)

The Kidney Disease: Improving Global Outcomes (KDIGO) criteria harmonize earlier RIFLE and AKIN definitions, staging AKI by either serum creatinine elevation or hourly urine output criteria (whichever metric is more severe determines the stage).

KDIGO Stage Serum Creatinine Criteria Urine Output Criteria

Stage 1 Increase of ≥ 0.3 mg/dL \ge 0.3\text{ mg/dL} ≥ 0.3 mg/dL ( ≥ 26.5 μ mol/L \ge 26.5\text{ }\mu\text{mol/L} ≥ 26.5 μ mol/L ) within 48 hours 48\text{ hours} 48 hours , OR Increase to 1.5 − 1.9 × 1.5-1.9\times 1.5 − 1.9 × baseline within 7 days 7\text{ days} 7 days < 0.5 mL/kg/hour <0.5\text{ mL/kg/hour} < 0.5 mL/kg/hour for 6 − 12 hours 6-12\text{ hours} 6 − 12 hours

Stage 2 Increase to 2.0 − 2.9 × 2.0-2.9\times 2.0 − 2.9 × baseline < 0.5 mL/kg/hour <0.5\text{ mL/kg/hour} < 0.5 mL/kg/hour for ≥ 12 hours \ge 12\text{ hours} ≥ 12 hours

Stage 3 Increase to 3.0 × 3.0\times 3.0 × baseline, OR Increase in serum creatinine to ≥ 4.0 mg/dL \ge 4.0\text{ mg/dL} ≥ 4.0 mg/dL ( ≥ 353.6 μ mol/L \ge 353.6\text{ }\mu\text{mol/L} ≥ 353.6 μ mol/L ), OR Initiation of Renal Replacement Therapy (RRT) , OR In patients < 18 <18 < 18 years, decrease in eGFR to < 35 mL/min/1.73 m 2 <35\text{ mL/min/1.73 m}^2 < 35 mL/min/1.73 m 2 < 0.3 mL/kg/hour <0.3\text{ mL/kg/hour} < 0.3 mL/kg/hour for ≥ 24 hours \ge 24\text{ hours} ≥ 24 hours , OR Anuria for ≥ 12 hours \ge 12\text{ hours} ≥ 12 hours

Etiological Classification and Diagnostic Differentiation of AKI

AKI is categorized anatomically into pre-renal, intrinsic (renal), and post-renal causes:

Pre-Renal Azotemia ( 55 − 60 % 55-60\% 55 − 60% of cases): Functional response to renal hypoperfusion without structural parenchymal damage. Etiologies include intravascular volume depletion (hemorrhage, gastrointestinal fluid loss, third-spacing), systemic vasodilation (distributive shock), cardiogenic pump failure, and drug-induced disruption of renal autoregulation (NSAIDs inhibit prostaglandin-mediated afferent arteriolar vasodilation; ACE inhibitors and ARBs inhibit angiotensin II-mediated efferent arteriolar vasoconstriction).

Intrinsic / Parenchymal AKI ( 35 − 40 % 35-40\% 35 − 40% of cases): Structural cellular damage involving the renal parenchyma. Most commonly Acute Tubular Necrosis (ATN) resulting from severe, prolonged ischemia or nephrotoxins (exogenous: aminoglycosides, vancomycin, amphotericin B, iodinated radiocontrast; endogenous: myoglobin from rhabdomyolysis, hemoglobin from intravascular hemolysis, Bence Jones proteins). Other intrinsic etiologies include acute interstitial nephritis (AIN) and rapidly progressive glomerulonephritis.

Post-Renal / Obstructive Uropathy ( < 5 % <5\% < 5% of ICU cases): Mechanical obstruction to urinary flow anywhere from the renal pelvis to the urethral meatus (benign prostatic hyperplasia, bilateral ureteral calculi, retroperitoneal fibrosis, neurogenic bladder, or an obstructed Foley catheter).

Biochemical Indices: Pre-Renal Azotemia vs Acute Tubular Necrosis

Diagnostic Parameter Pre-Renal Azotemia Intrinsic AKI (Acute Tubular Necrosis)

Pathophysiology Intact tubular function; avid sodium and water reabsorption in response to hypoperfusion Damaged tubular epithelial cells; inability to concentrate urine or reabsorb sodium

Fractional Excretion of Sodium ( FE Na \text{FE}_{\text{Na}} FE Na ​ ) < 1.0 % <1.0\% < 1.0% (often < 0.5 % <0.5\% < 0.5% ) > 2.0 % >2.0\% > 2.0% (often > 3.0 % >3.0\% > 3.0% )

Fractional Excretion of Urea ( FE Urea \text{FE}_{\text{Urea}} FE Urea ​ ) < 35 % <35\% < 35% (useful if patient received loop diuretics) > 50 % >50\% > 50%

Urinary Sodium Concentration ( U Na U_{\text{Na}} U Na ​ ) < 20 mmol/L <20\text{ mmol/L} < 20 mmol/L > 40 mmol/L >40\text{ mmol/L} > 40 mmol/L

Urine Osmolality ( U osm U_{\text{osm}} U osm ​ ) > 500 mOsm/kg >500\text{ mOsm/kg} > 500 mOsm/kg (hyperconcentrated) < 350 mOsm/kg <350\text{ mOsm/kg} < 350 mOsm/kg (isosthenuric, near plasma osmolality)

Blood Urea Nitrogen to Creatinine Ratio > 20 : 1 >20:1 > 20 : 1 (preferential passive urea reabsorption) < 15 : 1 <15:1 < 15 : 1

Urine Sediment Examination Hyaline casts, normal elements "Muddy brown" granular casts , renal tubular epithelial cells

FE Na = U Na × P Cr P Na × U Cr × 100 % \text{FE}_{\text{Na}} = \frac{U_{\text{Na}} \times P_{\text{Cr}}}{P_{\text{Na}} \times U_{\text{Cr}}} \times 100\% FE Na ​ = P Na ​ × U Cr ​ U Na ​ × P Cr ​ ​ × 100% FE Urea = U Urea × P Cr P Urea × U Cr × 100 % \text{FE}_{\text{Urea}} = \frac{U_{\text{Urea}} \times P_{\text{Cr}}}{P_{\text{Urea}} \times U_{\text{Cr}}} \times 100\% FE Urea ​ = P Urea ​ × U Cr ​ U Urea ​ × P Cr ​ ​ × 100%

Absolute Emergent Indications for Dialysis: The AEIOU Mnemonic

When medical management fails to stabilize homeostasis, emergent renal replacement therapy is indicated:

A — Acidosis: Severe metabolic acidosis with p H < 7.15 − 7.20 pH < 7.15-7.20 p H < 7.15 − 7.20 refractory to fluid resuscitation, source control, and conservative medical management, particularly when sodium bicarbonate infusion is contraindicated by hypernatremia or fluid overload.

E — Electrolytes: Severe, refractory hyperkalemia ( [ K + ] > 6.5 mmol/L [K^+] > 6.5\text{ mmol/L} [ K + ] > 6.5 mmol/L ) or rapidly rising potassium accompanied by electrocardiographic manifestations (peaked T waves, PR prolongation, loss of P waves, QRS widening, sine wave pattern) unresponsive to temporary shifting therapy (intravenous calcium gluconate/chloride for membrane stabilization, regular insulin with hypertonic dextrose, inhaled β 2 \beta_2 β 2 ​ -agonists).

I — Ingestions / Intoxications: Poisoning with dialyzable toxins characterized by low molecular weight ( < 500 Da <500\text{ Da} < 500 Da ), low volume of distribution ( V d < 1 − 2 L/kg V_d < 1-2\text{ L/kg} V d ​ < 1 − 2 L/kg ), low plasma protein binding, and high water solubility. Classic examples include methanol , ethylene glycol , lithium , salicylates (aspirin) , and theophylline .

O — Overload: Refractory volume overload (e.g., severe pulmonary edema, anasarca, intra-abdominal hypertension) unresponsive or resistant to high-dose intravenous loop diuretics (furosemide, bumetanide).

U — Uremia: Symptomatic organ dysfunction directly attributable to accumulation of uremic toxins, specifically: uremic pericarditis (friction rub, risk of hemorrhagic tamponade), uremic encephalopathy (asterixis, lethargy, seizures, coma), or uremic bleeding / platelet dysfunction .

Modalities of Renal Replacement Therapy: CRRT vs IHD

Feature Intermittent Hemodialysis (IHD) Continuous Renal Replacement Therapy (CRRT)

Duration 3 − 4 hours 3-4\text{ hours} 3 − 4 hours per session, 3 − 4 times/week 3-4\text{ times/week} 3 − 4 times/week Continuous 24 hours/day 24\text{ hours/day} 24 hours/day

Solute Flux Very high clearance rate per unit time Low, steady clearance rate over 24 hours 24\text{ hours} 24 hours

Hemodynamic Tolerance Poor in septic/unstable patients; rapid fluid removal triggers hypotension Superior hemodynamic stability ; gradual, continuous fluid removal

Intracranial Pressure (ICP) May induce cerebral edema due to rapid dialytic urea shift (dialysis disequilibrium) Maintains stable serum osmolality ; preferred in acute brain injury and liver failure

Clinical Indication Hemodynamically stable patients; acute life-threatening hyperkalemia or toxic ingestion Hemodynamically unstable, critically ill patients with septic shock, ARDS, or cerebral edema

CRRT Subtypes

Continuous Veno-Venous Hemofiltration (CVVH): Clearance driven exclusively by convection (solvent drag). Requires large volumes of sterile replacement fluid.

Continuous Veno-Venous Hemodialysis (CVVHD): Clearance driven exclusively by diffusion across a semipermeable membrane down a concentration gradient generated by counter-current dialysate flow. Does not require replacement fluid.

Continuous Veno-Venous Hemodiafiltration (CVVHDF): Combines convection and diffusion simultaneously. Utilizes both replacement fluid and dialysate fluid.

Slow Continuous Ultrafiltration (SCUF): Isolated fluid removal via ultrafiltration without replacement or dialysate fluids (fluid removal rate usually 100 − 300 mL/hour 100-300\text{ mL/hour} 100 − 300 mL/hour in fluid-overloaded patients without severe uremia or electrolyte crises).

Physical Principles of Solute Clearance: Diffusion vs Convection DIFFUSION (Hemodialysis) CONVECTION (Hemofiltration)

  • Dialysate Flow (Counter-Current) Hydrostatic Pressure Gradient (TMP)
  • ↓ ↓
  • [Concentration Gradient] [Bulk Solvent Drag]
  • ↓ ↓
  • High Clearance of Small Molecules High Clearance of Middle Molecules
  • (< 500 Da: Urea, K+, Creatinine) (500 Da - 30-40 kDa: Cytokines, Myoglobin)
  • 1. Diffusion

Mechanism: Passive movement of solute molecules down their concentration gradient across a semipermeable membrane, governed by Fick's first law of diffusion.

Determinants: Driven by counter-current dialysate flow relative to blood flow. Clearance is inversely proportional to the square root of solute molecular weight.

Molecular Selectivity: Highly efficient for small molecules ( < 500 Da <500\text{ Da} < 500 Da ) such as urea ( 60 Da 60\text{ Da} 60 Da ), potassium ( 39 Da 39\text{ Da} 39 Da ), sodium ( 23 Da 23\text{ Da} 23 Da ), and creatinine ( 113 Da 113\text{ Da} 113 Da ). Inefficient for larger solutes above 1,000 − 5,000 Da 1{,}000-5{,}000\text{ Da} 1 , 000 − 5 , 000 Da .

2. Convection ("Solute Drag")

Mechanism: Solutes are swept across a high-flux, large-pore membrane along with bulk solvent (plasma water) filtration driven by a transmembrane hydrostatic pressure gradient (TMP):

TMP = P filter, in + P filter, out 2 − P effluent \text{TMP} = \frac{P_{\text{filter, in}} + P_{\text{filter, out}}}{2} - P_{\text{effluent}} TMP = 2 P filter, in ​ + P filter, out ​ ​ − P effluent ​

Determinants: Solute clearance equals ultrafiltration rate ( Q uf Q_{\text{uf}} Q uf ​ ) multiplied by the sieving coefficient ( S S S ) of the membrane ( S = C filtrate / C plasma S = C_{\text{filtrate}} / C_{\text{plasma}} S = C filtrate ​ / C plasma ​ ). For solutes freely permeable across the membrane, S = 1.0 S = 1.0 S = 1.0 .

Molecular Selectivity: Highly effective for middle and large molecules ( 500 Da − 30 − 40 kDa 500\text{ Da} - 30-40\text{ kDa} 500 Da − 30 − 40 kDa ) such as β 2 \beta_2 β 2 ​ -microglobulin ( 11.8 kDa 11.8\text{ kDa} 11.8 kDa ), myoglobin ( 17 kDa 17\text{ kDa} 17 kDa ), and inflammatory cytokines (IL-6, TNF- α \alpha α ).

Pre-Dilution vs Post-Dilution Replacement in Hemofiltration

Pre-Dilution: Replacement fluid is infused into the blood circuit before it enters the hemofilter. Decreases circuit hematocrit and viscosity, prolonging filter life and reducing clotting, but lowers clearance efficiency by 10 − 15 % 10-15\% 10 − 15% because the entering solute concentration is diluted.

Post-Dilution: Replacement fluid is infused after the hemofilter. Maximizes concentration gradients and solute clearance efficiency, but causes hemoconcentration within the filter capillaries (higher hematocrit and protein concentration), increasing the risk of filter clotting.

Anticoagulation in CRRT: Regional Citrate vs Systemic Heparin

Circuit clotting is the primary technical cause of interrupted CRRT, blood loss, and reduced clearance efficacy.

1. Regional Citrate Anticoagulation (RCA) — The Gold Standard

KDIGO guidelines recommend Regional Citrate Anticoagulation as first-line therapy for CRRT in patients without contraindications.

Mechanism of Action: Trisodium citrate is infused continuously into the arterial (pre-filter) access line of the extracorporeal circuit. Citrate binds and chelates free ionized calcium ( C a 2 + Ca^{2+} C a 2 + ), forming soluble calcium-citrate complexes. Ionized calcium is an essential cofactor (Factor IV) required for multiple stages of the clotting cascade (tenase and prothrombinase complex activation). By lowering circuit ionized calcium to < 0.35 mmol/L <0.35\text{ mmol/L} < 0.35 mmol/L , the clotting cascade inside the filter is completely arrested.

Post-Filter Reversal: A substantial fraction of calcium-citrate complexes is removed in the effluent dialysate/ultrafiltrate. To prevent systemic hypocalcemia, calcium chloride or calcium gluconate is continuously infused into the venous return line (or via a separate central venous catheter) to restore systemic ionized calcium to normal ( 1.10 − 1.30 mmol/L 1.10-1.30\text{ mmol/L} 1.10 − 1.30 mmol/L ).

Advantages: Prolonged filter circuit life ( > 72 hours >72\text{ hours} > 72 hours ), significantly reduced systemic bleeding risks compared to heparin, and avoidance of Heparin-Induced Thrombocytopenia (HIT).

Citrate Metabolism and Citrate Toxicity ("Citrate Accumulation"):

Unfiltered calcium-citrate complexes entering the systemic circulation are metabolized predominantly by hepatocytes in the liver, skeletal muscle, and renal cortex via the Krebs cycle, with each citrate molecule generating 3 molecules of bicarbonate ( H C O 3 − HCO_3^- H C O 3 − ​ ) .

In severe hepatic failure, severe shock with tissue hypoperfusion, or mitochondrial dysfunction, systemic citrate metabolism fails, leading to citrate toxicity .

Diagnostic Hallmark: A Total Calcium to Ionized Calcium ratio ( [ Total Ca ] / [ iCa ] [\text{Total Ca}] / [\text{iCa}] [ Total Ca ] / [ iCa ] ) > 2.5 >2.5 > 2.5 (both measured in the same units, mmol/L \text{mmol/L} mmol/L ). Accompanied by refractory systemic ionized hypocalcemia, widening high anion gap metabolic acidosis (due to circulating citrate anions), and an escalating calcium infusion requirement.

2. Systemic Unfractionated Heparin

Mechanism: Binds antithrombin III, accelerating neutralization of thrombin (Factor IIa) and Factor Xa.

Monitoring: Titrated to achieve an activated partial thromboplastin time (aPTT) of 1.5 − 2.0 × 1.5-2.0\times 1.5 − 2.0 × baseline or anti-Xa activity of 0.3 − 0.5 IU/mL 0.3-0.5\text{ IU/mL} 0.3 − 0.5 IU/mL .

Limitations: Substantial risk of systemic hemorrhage ( 10 − 15 % 10-15\% 10 − 15% ), unpredictable pharmacokinetics in critical illness, risk of Heparin-Induced Thrombocytopenia (HIT), and premature circuit clotting in patients with antithrombin III deficiency (common in sepsis).

Clinical Pearls and Exam Traps

The Diuretic FE-Na Trap: In patients who have received loop diuretics within 24 − 48 hours 24-48\text{ hours} 24 − 48 hours , the FE Na \text{FE}_{\text{Na}} FE Na ​ is falsely elevated because loop diuretics block the N a + / K + / 2 C l − Na^+/K^+/2Cl^- N a + / K + /2 C l − cotransporter in the thick ascending limb of Henle, forcing urinary sodium excretion even in true pre-renal states. Always calculate the Fractional Excretion of Urea ( FE Urea \text{FE}_{\text{Urea}} FE Urea ​ ) in patients taking diuretics: an FE Urea < 35 % \text{FE}_{\text{Urea}} < 35\% FE Urea ​ < 35% confirms pre-renal azotemia.

Citrate Toxicity vs Normal Citrate Metabolism: Candidates often confuse citrate toxicity with normal citrate metabolism. Normal citrate metabolism yields an excess of bicarbonate, causing metabolic alkalosis . Citrate toxicity (accumulation without hepatic metabolism) results in high anion gap metabolic acidosis , profound ionized hypocalcemia, and a total-to-ionized calcium ratio > 2.5 >2.5 > 2.5 .

AEIOU Timing in Sepsis: Early observational trials suggested benefit from early initiation of RRT, but large multicenter randomized trials (AKIKI, IDEAL-ICU, STARRT-AKI) demonstrated that an accelerated initiation strategy does not improve survival compared to a watchful waiting strategy that initiates RRT only upon developing conventional absolute indications (the AEIOU criteria).